vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and FLYEXCLUSIVE INC. (FLYX). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $92.1M, roughly 1.8× FLYEXCLUSIVE INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 19.8%). Over the past eight quarters, FLYEXCLUSIVE INC.'s revenue compounded faster (21.9% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
FLYEXCLUSIVE INC. is a U.S.-headquartered private aviation services provider that offers private jet charter, aircraft management, maintenance repair, and fractional ownership programs. It primarily serves high-net-worth individuals, corporate clients, and government entities across North America, delivering personalized on-demand air travel solutions prioritizing safety and convenience.
ESPR vs FLYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $92.1M |
| Net Profit | — | $-4.3M |
| Gross Margin | — | 13.7% |
| Operating Margin | 50.6% | -12.3% |
| Net Margin | — | -4.6% |
| Revenue YoY | 143.7% | 19.8% |
| Net Profit YoY | — | 32.0% |
| EPS (diluted) | $0.32 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | — | ||
| Q3 25 | $87.3M | $92.1M | ||
| Q2 25 | $82.4M | $91.3M | ||
| Q1 25 | $65.0M | $88.1M | ||
| Q4 24 | $69.1M | — | ||
| Q3 24 | $51.6M | $76.9M | ||
| Q2 24 | $73.8M | $79.0M | ||
| Q1 24 | $137.7M | $80.0M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $-4.3M | ||
| Q2 25 | $-12.7M | $-4.8M | ||
| Q1 25 | $-40.5M | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $-6.3M | ||
| Q2 24 | $-61.9M | $-5.2M | ||
| Q1 24 | $61.0M | $-5.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 13.7% | ||
| Q2 25 | — | 15.0% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 11.3% | ||
| Q2 24 | — | 7.9% | ||
| Q1 24 | — | 7.2% |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | -12.3% | ||
| Q2 25 | 8.6% | -13.5% | ||
| Q1 25 | -34.0% | -16.7% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | -27.2% | ||
| Q2 24 | 3.5% | -27.6% | ||
| Q1 24 | 52.5% | -34.3% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | -4.6% | ||
| Q2 25 | -15.4% | -5.2% | ||
| Q1 25 | -62.2% | -6.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -8.2% | ||
| Q2 24 | -83.9% | -6.5% | ||
| Q1 24 | 44.3% | -7.3% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | $-0.25 | ||
| Q2 25 | $-0.06 | $-0.26 | ||
| Q1 25 | $-0.21 | $-0.30 | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | $-0.32 | ||
| Q2 24 | $-0.33 | $-0.32 | ||
| Q1 24 | $0.34 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $18.7M |
| Total DebtLower is stronger | — | $123.9M |
| Stockholders' EquityBook value | $-302.0M | $-434.2M |
| Total Assets | $465.9M | $448.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | $18.7M | ||
| Q2 25 | $86.1M | $15.8M | ||
| Q1 25 | $114.6M | $14.7M | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | $18.7M | ||
| Q2 24 | $189.3M | $9.3M | ||
| Q1 24 | $226.6M | $5.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $123.9M | ||
| Q2 25 | — | $111.6M | ||
| Q1 25 | — | $121.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $197.9M | ||
| Q2 24 | — | $206.3M | ||
| Q1 24 | — | $209.4M |
| Q4 25 | $-302.0M | — | ||
| Q3 25 | $-451.4M | $-434.2M | ||
| Q2 25 | $-433.5M | $-261.4M | ||
| Q1 25 | $-426.2M | $-281.5M | ||
| Q4 24 | $-388.7M | — | ||
| Q3 24 | $-370.2M | $-192.0M | ||
| Q2 24 | $-344.2M | $-149.7M | ||
| Q1 24 | $-294.3M | $-149.5M |
| Q4 25 | $465.9M | — | ||
| Q3 25 | $364.0M | $448.1M | ||
| Q2 25 | $347.1M | $443.4M | ||
| Q1 25 | $324.0M | $466.8M | ||
| Q4 24 | $343.8M | — | ||
| Q3 24 | $314.1M | $487.1M | ||
| Q2 24 | $352.3M | $494.7M | ||
| Q1 24 | $373.1M | $524.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-209.0K |
| Free Cash FlowOCF − Capex | — | $-11.0M |
| FCF MarginFCF / Revenue | — | -12.0% |
| Capex IntensityCapex / Revenue | 0.0% | 11.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-51.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | — | ||
| Q3 25 | $-4.3M | $-209.0K | ||
| Q2 25 | $-31.4M | $363.0K | ||
| Q1 25 | $-22.6M | $-10.5M | ||
| Q4 24 | $-35.0M | — | ||
| Q3 24 | $-35.3M | $-12.3M | ||
| Q2 24 | $-7.2M | $-16.2M | ||
| Q1 24 | $53.8M | $-26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-11.0M | ||
| Q2 25 | — | $353.0K | ||
| Q1 25 | — | $-14.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | $-25.7M | ||
| Q2 24 | $-7.3M | $-26.6M | ||
| Q1 24 | $53.8M | $-64.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | -12.0% | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | -16.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | -33.5% | ||
| Q2 24 | -9.9% | -33.7% | ||
| Q1 24 | 39.0% | -80.6% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 11.7% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 4.7% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | 17.5% | ||
| Q2 24 | 0.1% | 13.2% | ||
| Q1 24 | 0.1% | 48.2% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FLYX
Segment breakdown not available.
